Letter to the EditorFailure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study
Section snippets
Funding support
None.
Disclosure of interest
X.P.: Research grant from Pfizer.
OL: research grant from Pfizer.
The other authors declare that they have no competing interest.
Acknowledgement
We are grateful to Anaïs Maugard and Hélène Bodilis for administrative support, to Hicham Kardaoui for data acquisition and to Mathilde Bahuaud who performed the ELISA serotype monitoring.
References (8)
- et al.
A new endpoint definition improved clinical relevance and statistical power in a vaccine trial
J Clin Epidemiol
(2009) - et al.
Long-term outcomes of the WEGENT trial on remission-maintenance for granulomatosis with polyangiitis or microscopic polyangiitis
Arthritis Rheum
(2016) - et al.
Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients
Medicine (Baltimore)
(2005) - et al.
Long-term patient survival in ANCA-associated vasculitis
Ann Rheum Dis
(2011)
There are more references available in the full text version of this article.
Cited by (10)
Recommendations for prevention of infection in systemic autoimmune rheumatic diseases
2022, Reumatologia ClinicaRecommendations of the Brazilian Society of Rheumatology for induction therapy of ANCA‐associated vasculitis
2017, Revista Brasileira de ReumatologiaEosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease
2020, Expert Review of Clinical Immunology
© 2016 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.